Detailed Information on Publication Record
2023
Why are not all eligible CML patients willing to attempt TKI discontinuation?
ŽÁČKOVÁ, DanielaBasic information
Original name
Why are not all eligible CML patients willing to attempt TKI discontinuation?
Authors
ŽÁČKOVÁ, Daniela (203 Czech Republic, guarantor, belonging to the institution)
Edition
25th Annual John Goldman International Conference on Chronic Myeloid Leukemia: Biology and Therapy, Mandelieu-La Napoule, Francie, 2023
Other information
Language
English
Type of outcome
Vyžádané přednášky
Field of Study
30230 Other clinical medicine subjects
Country of publisher
France
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
RIV identification code
RIV/00216224:14110/23:00133248
Organization unit
Faculty of Medicine
Keywords (in Czech)
chronic myeloid leukemia; TFR; HALF; CLINICAL TRIAL
Keywords in English
chronic myeloid leukemia; TFR; HALF; CLINICAL TRIAL
Tags
International impact
Změněno: 26/1/2024 10:52, Bc. Hana Vladíková, BBA
Abstract
V originále
A prospective phase II clinical trial evaluating the efficacy and safety of tyrosine kinase inhibitor withdrawal after prior two-step dose reduction in patients with chronic myeloid leukemia in deep molecular remission The HALF clinical trial is designed as a prospective, multicenter, nonrandomized, open-label phase II study to assess the efficacy and safety of tyrosine kinase inhibitor withdrawal after a prior two-step dose reduction in patients with chronic myeloid leukemia in deep remission. The clinical evaluation of HALF could contribute to the formulation of a new disease management strategy for patients achieving sustained remission with the potential for wider benefits not only for the patients themselves, but also for the healthcare system.
Links
| 90249, large research infrastructures |
|